


RealRate

PHARMACEUTICAL 2017

Neoleukin Therapeutics Inc. Rank 18 of 292









PHARMACEUTICAL 2017



RealRate

Neoleukin Therapeutics Inc. Rank 18 of 292

The relative strengths and weaknesses of Neoleukin Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neoleukin Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Neoleukin Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 258%, being 255% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	103,485
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,519
Liabilities, Non-Current	197
Other Assets	50,046
Other Compr. Net Income	121
Other Expenses	0
Other Liabilities	0
Other Net Income	643
Other Revenues	0
Property and Equipment	849
Research and Development	28,382
Selling, General and Administrative Expense	9,263

Output Variable	Value in 1000 USD
Assets	154,380
Liabilities	9,716
Expenses	37,645
Revenues	0
Stockholders Equity	144,664
Net Income	-37,002
Comprehensive Net Income	-36,942
Economic Capital Ratio	258%

